Pinealon

A short bioregulator tripeptide (Glu-Asp-Arg) that specifically targets brain tissue, developed as part of the Khavinson peptide bioregulation program. Pinealon penetrates the blood-brain barrier and has demonstrated neuroprotective, cognitive-enhancing, and anti-aging effects on central nervous system tissues in preclinical studies.

• Modulates gene expression in neuronal cells to promote survival pathways
• Enhances antioxidant defense in brain tissue
• Regulates pineal gland peptide and melatonin production
• Supports synaptic plasticity and neurotransmitter balance

• Active neurological conditions requiring medication (consult physician)
• Concurrent use of sedatives or CNS depressants (may potentiate effects)
• Pregnancy or breastfeeding

Store capsules at room temperature (15–25°C (59–77°F)) in a cool, dry place. Injectable form: store at 2–8°C (36–46°F). Stable due to short peptide structure.

Preclinical studies have demonstrated that Pinealon protects neurons from hypoxia-induced and oxidative damage, promoting cell survival in cortical neuron cultures. Gene expression studies show modulation of apoptosis-related genes and antioxidant enzymes. In aged animal models, Pinealon courses improved learning, memory, and neuronal density. Part of the Khavinson bioregulator program that has produced over 200 publications on short peptide bioregulation. No large-scale Western clinical trials to date.